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Type 2 diabetes is a key risk factor for ischemia-de-
pendent pathology; therefore, a significant medical
need exists to develop novel therapies that increase
the formation of new vessels. We explored the thera-
peutic potential of epidermal growth factor receptor
tyrosine kinase (EGFRtk) and extracellular signal–reg-
ulated kinase 1/2 (ERK1/2) inhibition in impaired
ischemia-induced neovascularization in type 2 diabe-
tes. Unilateral femoral artery ligation was performed
in diabetic (db/db) and their control (db/db)
mice for 4 weeks, followed by treatments with EGFRtk
and ERK1/2 inhibitors (AG1478, 10 mg/kg/day and
U0126, 400 g/kg/day, respectively) for 3 weeks. Neo-
vascularization, blood flow recovery, vascular and
capillary density, and endothelial nitric oxide syn-
thase activity were significantly impaired and were
associated with enhanced EGFRtk and ERK1/2 activity
in db/db mice. EGFRtk and ERK1/2 inhibitors did
not have any effect in control mice, while in db/db
mice there was a significant increase in neovascu-
larization, blood flow recovery, vascular and capil-
lary density, endothelial nitric oxide synthase ac-
tivity, and were associated with a decrease in
EGFRtk and ERK1/2 activity. Our data demonstrated
that the inhibition of EGFRtk and ERK1/2 restored
ischemia-induced neovascularization and blood
flow recovery in type 2 diabetic mice. Thus, EGFRtk
and ERK1/2 could be possible targets to protect from
410ischemia-induced vascular pathology in type 2
diabetes. (Am J Pathol 2012, 180:410–418; DOI:
10.1016/j.ajpath.2011.09.016)
Almost 26 million Americans have diabetes and
650,000 new cases are diagnosed every year.1 Large
epidemiological studies reveal that diabetes is linked to
metabolic syndrome and vascular disease.2 Diabetes is
a powerful risk factor for coronary artery disease, stroke,
and peripheral arterial disease.3 Because the formation
of new vessels in response to ischemia is compromised,
diabetes significantly accelerates lower extremity arterial
disease and accounts for 60% of all nontraumatic limb
amputations in the Unites States.4 In addition, previous
studies reported abnormalities in neovascularization in
diabetic patients and animal models with peripheral ar-
tery disease.5,6 However, the underlying mechanism re-
sponsible for impaired ischemia-induced neovascular-
ization in type 2 diabetes is still unclear.
Loss of a limb produces a permanent disability that
can impact a patient’s self-image, self-care, and mobility,
which negatively affects society. Therefore, there is a
significant medical need to develop novel therapies to
increase the formation of new vessels, especially in pa-
tients with type 2 diabetes. Because well-developed new
blood vessels are known to lower ischemia-induced pa-
thology, we speculate that the restoration of tissue blood
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significantly improve patient outcome.
In a previous study, we demonstrated that enhanced
epidermal growth factor receptor tyrosine kinase
(EGFRtk) activity is involved in microvascular dysfunction
in type 2 diabetes.7 We also observed that the mitogen-
activated protein kinase (MAPK) family proteins extracel-
lular signal-regulated kinase 1 and 2 (ERK1/2) are impli-
cated in the homeostasis of microvessels. EGFRtk
consists of a 1186-amino acid glycoprotein containing a
single trans-membrane domain with intracellular portion
containing the tyrosine kinase domain.7 EGFRtk can be
activated by different ligands such as EGF and heparin-
binding EGF-like factor.8 Although the involvement of
EGFRtk is well documented in tumor angiogenesis, the
role of EGFRtk and the downstream signaling (ERK1/2) in
neovascularization in the ischemic hind limb of type 2
diabetic mice is not known. Thus, the purpose of this
study was to determine the potential therapeutic effect of
EGFRtk and ERK1/2 inhibition to treat impaired ischemia-
induced vascular pathology in type 2 diabetic mice.
Materials and Methods
Animal Model and Surgery
Obese homozygote (db/db) type 2 diabetic mice lack-
ing the gene encoding for leptin receptor (Lepr) (dia-
betic, 8 to 10 weeks old) and their control heterozygote
Lepr db/db (db/db) nondiabetic (control, 8 to 10
weeks old) adult male mice were obtained from the Jack-
son Laboratories (Bar Harbor, ME). The hind-limb isch-
emia procedure was performed in all mice by ligation of
the proximal segment of the right femoral artery for 4
weeks, as previously described,6,9 and then 3 weeks of
treatment in the following groups: control mice without
treatment (n  10); control mice treated with AG1478 (10
mg/kg/day in mini-osmotic pumps, n  10); control mice
treated with U0126 (400 g/kg/day in mini-osmotic
pumps, n 10); diabetic mice without treatment (n 10);
diabetic mice treated with AG1478 (LC Laboratories,
Woburn, MA; 10 mg/kg/day in mini-osmotic pumps, n 
10); and diabetic mice treated with U0126 (LC Laborato-
ries; 400 g/kg/day in mini-osmotic pumps, n  10).
These studies are conformed to the principles of the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Tulane
University Institutional Animal Care and Use Committee.
Blood Glucose
Blood glucosemeasurements were obtained from tail blood
samples using a blood glucose meter (Prestige Smart Sys-
tem HDI; Home Diagnostics, Inc., Fort Lauderdale, FL) in all
groups of mice after a 6 hours fast.6
Insulin Resistance
Insulin level was determined at the end of treatment using
the Ultrasensitive Mouse Insulin enzyme-linked immu-nosorbent assay (ELISA) protocol (Mercodia, Uppsala,
Sweden), which estimates steady-state insulin resis-
tance.6
Blood Pressure
Systolic blood pressure (SBP) was measured by tail-cuff
plethysmography (Softron, BP-98A), before treatment
and then once a week as previously described.6,10 All
mice were trained for tail cuff plethysmography 1 week
before the experiments. SBP was measured in conscious
mice using the CODA tail-cuff blood pressure system
(Kent Scientific, Torrington, CT). Systolic arterial blood
pressure measurements were performed at the same
time (between 9 and 11 AM) to avoid the influence of the
circadian cycle, and the value for SBP was obtained by
estimating the average of eight measurements for a sin-
gle measurement.
Laser Doppler Measurement of Hind-Limb
Blood Flow
Each mouse was warmed to a core temperature of 37°C,
and then hind-limb blood flow measurements over the
region of interest were performed before surgery, imme-
diately after surgery, and serially over a 7-week period
with laser Doppler perfusion imaging (LDPI) (Moor Instru-
ments, Wilmington, DE). The blood flow of right and left
hind limbs was assessed by scanning the same lower
abdomen region and limbs of mice with a laser Doppler
blood flow meter as previously reported.6
X-Ray Quantification of the Hind-Limb
Angiogenesis
Vessel density was assessed by microangiography at the
end of the treatment period, as previously described.6,11
Briefly, mice were anesthetized and a contrast medium
(barium sulfate, 0.5 g/mL) was injected through a cathe-
ter introduced into the abdominal aorta. The vessel den-
sity quantification was determined using Multi Gauge Fu-
jifilm (Tokyo, Japan).
Colorimetric Determination of cGMP
cGMP levels were measured in hind-limb muscle in all
groups of mice. Mice were sacrificed and hind-limb mus-
cles were immediately harvested and frozen in liquid
nitrogen. Measurements were performed using a sand-
wich enzyme-linked immunosorbent assay (cGMP en-
zyme-linked immunosorbent assay kit; Cayman Chemi-
cal, Ann Arbor, MI) according to the manufacturer
instructions and as previously described.6,12
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed.6,13 After 7 weeks, mice were anesthetized and
perfused with formalin for 45 minutes. Hind-limb muscles
were then harvested, embedded in paraffin, and sec-
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95°C for 40 minutes for antigen retrieval. After blocking
with 5% BSA in phosphate-buffered saline (PBS), sec-
tions were incubated overnight at 4°C with rabbit mono-
clonal antibody against CD31 (BD Pharmigen, San Jose,
CA), -actin (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). For every section, a negative control without primary
antibody was processed simultaneously. After 15 min-
utes of washing in PBS, a secondary rabbit antibody
coupled to Alexa Fluor (Molecular Probes, Carlsbad, CA)
was added for 1 hour at room temperature. Cell nuclei
were counterstained with DAPI (Molecular Probes). Stain-
ing was evaluated using fluorescent a microscope. The
capillary density was then determined by counting the
number of capillaries in each section of muscle.
RT-PCR Assay
EGFR, vascular endothelial growth factor (VEGF), endo-
thelial nitric oxide synthase (eNOS), and MAPK1 mRNA
levels were determined in hind-limb tissues from control
and diabetic mice. Total RNA was obtained using the
RNeasy Fibrous Tissue Mini Kit (Quiagen, Valencia, CA)
according to the manufacturer’s recommendations. A to-
tal of 1 g of DNase I-treated RNA was reverse tran-
scribed into cDNA using the High Capacity cDNA Ar-
chive Kit (Applied Biosystems, Foster City, CA) with
random hexamers in a 20 L reaction. PCR was per-
formed in duplicate for each sample using 1 L of cDNA
as a template, 1 of TaqMan Universal PCR Master Mix
(Applied Biosystems), and 10 of TaqMan Gene Expres-
sion Assays (Applied Biosystems) in a 20 L reaction.
Assays-on-Demand (Applied Biosystems) of TaqMan flu-
orescent real-time PCR primers and probes were used
for EGFR (Mm 00433023_m1), VEGF (Mm01281449_m1),
eNOS (Mm00435217_m1), MAPK1 (Mm00442479_m1),
and18S rRNA (Hs99999901_s1), which was used as an
endogenous control to normalize results. Quantitative re-
verse transcription-PCR was carried out in an Mx 3000
RT-PCR platform (Agilent Technologies Stratagene, La
Jolla, CA) using the following conditions: 1 minute at
50°C, 10 minutes at 95°C followed by 40 cycles of 15
seconds at 95°C, and 1 minute at 60°C. Relative EGFR,
VEGF, eNOS, and MAPK1 mRNA levels were determined
using the Ct method. Results are expressed as the
relative expression of mRNA in the treated control and
db/db mice compared with untreated control mice.
Figure 1. Blood glucose, body weight, insulin, and blood pressure in contr
(U0). A: Comparison of blood glucose levels between control and diabetic mi
control and diabetic mice with or without AG1478 or U0126, n  10. C: Serum insu
D: Blood pressure measurements with tail-cuff methods in all groups, n  10.Western Blot Analysis
Western blot analysis was performed as previously de-
scribed.7,10 We used Western blot analysis to assess the
phosphorylation and expression of ERK1/2 (Promega,
Madison, WI), EGFR (ECM Biosciences, Versailles, KY),
eNOS (Cell Signaling, Boston, MA), expression of VEGF
(Cell Signaling), and glyceraldehyde-3-phosphate dehy-
drogenase (Cell Signaling) using specific antibodies. The
quantification of Western blot was determined using Fu-
jifilm-Multi Gauge software.
Statistical Analysis
Results are expressed as mean  SEM. One-way or
two-way analysis of variance was used to compare
each parameter when appropriate. Comparisons be-
tween groups were performed with t-tests when the
analysis of variance test was statistically significant.
Values of P  0.05 were considered significant. Differ-
ences between specified groups were analyzed using
the Student’s t-test (two-tailed) for comparing two
groups with P  0.05 considered statistically signifi-
cant.
Results
Effect of EGFRtk and ERK1/2 Inhibition on
Blood Glucose, Insulin Levels, Body Weight,
and SBP
Blood glucose, insulin levels and body weight were
increased in diabetic than in control mice; and were
not affected by the treatments (Figure 1, A–C). Systolic
blood pressure was similar in all groups of mice
(Figure 1D).
Effect of EGFRtk and ERK1/2 MAP Kinase
Inhibition on Blood Flow
Blood flow was measured using Doppler-flow before,
just after surgery, and then once a week for 7 weeks in
all groups of mice (Figure 2, A and B). Blood flow was
significantly decreased to 5% of control value after
femoral artery ligation in all groups of mice. After 4
weeks, blood flow recovery in control mice was
and diabetic mice treated with and without (None) AG1478 (AG) or U0126
r without AG1478 or U0126, n 10. B: Comparison of body weight betweenol mice
ce with olin levels in all groups, (n  10); *P  0.05 for diabetic versus control mice.
ce betw
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cantly reduced in the ischemic hind limb from diabetic
mice compared with control mice. Four weeks after
surgery, control and diabetic mice were then treated
with AG1478 or U0126 for 3 weeks. Intriguingly, Figure
2A and B revealed a significant increase in blood flow
recovery in the ischemic hind limb from diabetic mice
Figure 2. Blood flow analysis in hind limb in diabetic and control mice. A: B
surgery and once a week for 7 weeks (n 10). B:Quantitative data of blood
versus control, †P  0.05 for diabetic treated with U0126 versus diabetic mic
AG1478. Red arrow represents macrophages. C: Quantitative data of blood
EGF or with EGF  U0126, (n  5); *P  0.05 indicating a significant differen
0.05 for nontreated control versus control treated with EGF.treated with AG1478 or U0126 in comparison with non-treated diabetic mice. The chronic treatment with
AG1478 and U0126 did not affect blood flow in control
mice (Figure 2, A and B).
To determine the direct effect of EGFRtk and ERK1/2
on blood flow recovery regulation, control mice that had
femoral artery ligation were locally injected, in the isch-
emic hind limb, with exogenous EGF (50 ng/mouse) with
w was measured with MoorLDI-Laser in all groups before surgery, just after
asurements with MoorLDI-Laser in all groups, (n 10); *P 0.05 for diabetic
 0.05 statistically significant between diabetic versus diabetic treated with
lysis in hind limb of nontreated control mice and control mice injected with
een control treated with EGF  U0126 versus control treated with EGF, †P lood flo
flow me
e, and ‡P
flow anaor without U0126 (400 g/kg/day) for 3 weeks. Data re-
ence be
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duced blood flow recovery, which was prevented with
pretreatment of mice with U0126 (Figure 2C).
Effect of EGFRtk and ERK1/2 Inhibition on
Vessel and Capillary Density, and cGMP
Content
At the end of the experiment, we evaluated vessel density
with high-definition microangiography. Contrast media
(barium sulfate, 0.5 g/mL) was injected into abdominal
aorta. Angiographic measurement of right and left hind
limbs was determined using digital X-ray (Figure 3A).
Vessel density was quantified with Fujifilm-Multi Gauge
software (Figure 3C). Ischemic hind-limb vessel density
was similar in control groups of mice with or without
treatment. In contrast, vessel density in nontreated dia-
betic mice was significantly lower compared with control
mice. In diabetic mice treated with AG1478 or U0126,
vessel density was significantly increased compared with
nontreated diabetic mice (Figure 3, A and C).
Blood flow recovery and microangiographic data were
Figure 3. A: Microangiography at the end of the treatment period in all grou
is representative of n  4. Red arrows indicate femoral artery ligation. B: Ex
(red staining), and nucleus (blue staining) in ischemic hind limbs. White arr
in lower right panel. C: Quantitative data (score in percent) showing vess
measurements in all groups, n  4. D: Quantitative data of CD31 staining i
*P  0.05 for diabetic versus control, ‡P  0.05 indicating a significant differ
diabetic versus diabetic treated with U0126 (U0).confirmed by capillary density analysis using the CD31staining (Figure 3B). Capillary density in the ischemic
hind limb was similar in control groups of mice with or
without treatment. A significant increase in the capillary
density was observed in the ischemic hind limb from
diabetic mice treated with AG1478 or U0126 compared
with nontreated diabetic mice (Figure 3D).
Colorimetric determination of cGMP content in isch-
emic hind-limb muscle lysates was performed in all
groups of mice. The cGMP level was significantly lower in
ischemic hind limb in diabetic mice than in control mice.
Diabetic mice treated with AG1478 or U0126 displayed a
significant increase in cGMP level compared with non-
treated diabetic mice (Figure 3E).
Effect of EGFRtk and ERK1/2 Inhibition on
mRNA Level of MAPK, EGFRtk, VEGF,
and eNOS
We determined mRNA levels of EGFR, VEGF, MAPK1,
and eNOS in ischemic hind limbs from all groups of mice.
Figure 4A illustrates that MAPK1 mRNA level was ele-
vated in diabetic mice compared with control mice. The
es were assembled to obtain a complete view of the hind limb; each picture
f immunostaining with specific antibodies for CD31 (green staining), -actin
icate -actin in top left panel, CD31 in top right panel, and combination
ty in hind limb using Multi Gauge - FUJIFILM by selecting the same area of
imb in all groups. E: cGMP levels in ischemic hind limb in all groups. C–E:
tween diabetic versus diabetic treated with AG1478 (AG), and †P  0.05 forps. Imag
ample o
ows ind
el densi
n hind ltreatment with AG1478 and U0126 did not affect the
nontrea
ant diffe
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(Figure 4A). EGFRtk mRNA level was higher in diabetic
mice compared with control mice (Figure 4B). Treatment
with AG1478 and U0126 did not affect the mRNA level of
EGFRtk in control mice but was significantly reduced in
diabetic mice (Figure 4B). The mRNA level for eNOS in all
groups was not changed (Figure 4C). VEGF mRNA level
was increased in diabetic mice compared with control
mice with and without treatment (Figure 4D). The treat-
ment with AG1478 and U0126 reduced the mRNA level
for VEGF in diabetic mice (Figure 4D).
Effect of EGFRtk and ERK1/2 Inhibition on the
Expression and Phosphorylation Level of
ERK1/2, EGFRtk, eNOS, and VEGF
Figure 5A illustrates an increase in ERK1/2 expression
and phosphorylation in diabetic mice compared with
control mice. The treatment with AG1478 and U0126 did
not affect ERK1/2 expression but significantly reduced
phosphorylation levels in diabetic mice (Figure 5A). In
control mice, the treatment did not affect ERK1/2 expres-
sion and phosphorylation (Figure 5A). We also measured
the expression and phosphorylation of EGFRtk in all
groups of mice. The data revealed an increase in EGFRtk
expression and phosphorylation in diabetic mice, which
was significantly reduced by AG1478 and U0126 treat-
ment (Figure 5B). In control mice, AG1478 and U0126
had no effect on EGFRtk expression and phosphorylation
(Figure 5B). The expression and phosphorylation of
eNOS were significantly reduced in diabetic mice com-
pared with control mice (Figure 5C). Chronic treatment
with AG1478 and U0126 increased eNOS expression
and phosphorylation in diabetic mice but no effect was
observed in control mice (Figure 5C). The VEGF expres-
sion was significantly higher in diabetic mice compared
treated diabetic mice and all control groups of mice
(Figure 5D).
Discussion
Impaired ischemia-induced neovascularization is a major
risk factor for amputation, stroke, and heart attack in type
2 diabetic patients, which represents a major public
Figure 4. Quantitative reverse transcription-PCR assessment of (A) MAPK1
in ischemic hind-limb muscles in control and diabetic mice with or without AG
A–D: Results are expressed as the relative expression of mRNA compared to
versus diabetic treated with U0126 (U0), and ‡P  0.05 indicating a significhealth issue in the United States and worldwide. Theability to elicit a neovascularization response varies con-
siderably between tissues, species, and even individual
patients with similar degrees of ischemia burden. Under-
standing the key regulatory processes is critical for de-
veloping a new strategy for a potential therapy. In the
present study, we demonstrated for the first time the
involvement of EGFRtk and ERK1/2 in the impaired isch-
emia-induced neovascularization in type 2 diabetic mice.
Importantly, chronic inhibition of EGFRtk and ERK1/2 re-
stored ischemia-induced neovascularization and subse-
quently blood flow recovery in type 2 diabetic mice.
The induction of neovascularization is thought to be
dependent on variety of factors that include cell therapy
(stem cells), intermediate signaling (nitric oxide-cGMP),
and growth factors (VEGF and EGF).6,14–16 Signaling
through EGFR is generally believed to be angiogenic17 in
cancer and its inhibition suppresses angiogenesis. The
EGFR signaling is completely dysregulated in tumors due
to different somatic mutations in the EGF receptor, as it
has been previously reported.18,19 In our previous stud-
ies, we demonstrated that the enhanced EGFRtk phos-
phorylation level in type 2 diabetic mice is responsible for
microvascular dysfunction. Interestingly the inhibition of
EGFRtk reduced EGFR phosphorylation and improved
microvascular function in db/db mice.7 In the present
study, the inhibition of EGFRtk increases ischemia-in-
duced neovascularization. Therefore, it is important to
mention that cancer and vascular complications in type 2
diabetes are two different diseases in terms of etiology
and mechanisms.
We also showed that ERK1/2, downstream signaling of
the EGFRtk, is an important key element in the homeo-
stasis of microvessels.7 Thus, the present study was car-
ried out to chronically inhibit EGFRtk and ERK1/2 and
restore ischemia-induced neovascularization in type 2
diabetic mice. Our protocol was first to induce ischemia
in hind limb of diabetic and control mice for 4 weeks and
then treat the mice with EGFRtk and ERK1/2 inhibitors for
3 weeks.
Glucose, insulin levels and body weight were elevated
in diabetic mice compared with control mice. The chronic
treatment did not affect these values indicating that
EGFRtk and ERK1/2 are not involved in the etiology but
rather the consequence of type 2 diabetes. The systolic
, (B) EGFR (n  5), (C) eNOS (n  5), and (D) VEGF (n  5) mRNA levels
U0126. The mRNA level was normalized to 18S rRNA as endogenous control.
ted control mice; *P  0.05 for diabetic versus control, †P  0.05 for diabetic
rence between diabetic versus diabetic treated with AG1478 (AG).(n  5)
1478 orblood pressure was normal in all groups of mice suggest-
xpressio
.05 for d
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ment did not affect arterial blood pressure.
When control and diabetic mice hind limbs were first
subjected to ischemia for 4 weeks, blood flow recovery
was 100% in control mice compared with 49% in diabetic
mice. These data clearly indicate that blood flow recovery
in type 2 diabetes is compromised and suggests that
neovascularization in response to chronic ischemia is
impaired. These data are in agreement with previous
studies showing that neovascularization is altered in type
2 diabetic patients and animal models.6,21,22 Importantly,
the treatment of diabetic mice with EGFRtk or ERK1/2
inhibitors, started 4 weeks after femoral artery ligation,
restored blood flow recovery reaching 100%. These
novel findings demonstrate that EGFRtk and ERK1/2 are
important factors in the impaired ischemia-induced neo-
vascularization response and are independent of glu-
cose, insulin and obesity regulation; and could be down-
stream to the effects of hyperglycemia and insulin
resistance.
Using an alternative strategy, we evaluated vessel and
capillary density in the ischemic hind limb of all groups of
Figure 5. Western blot analysis of (A) total and phosphorylated ERK1/2 (n 
(n 5), and (D) VEGF (n 5) protein levels in ischemic hind-limb muscles in
are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) e
difference between diabetic versus diabetic treated with U0126, and ‡P  0mice. We observed that vessel and capillary density weresignificantly reduced in diabetic mice compared with
control mice. Importantly, vessel and capillary density in
diabetic mice was reversed by AG1478 or U0126 treat-
ments. These data strengthen our previous findings indi-
cating23 that EGFRtk and ERK1/2 are critical in this pro-
cess. These data are in agreement with our previous data
showing an induction of structural wall remodeling of
resistance arteries, which was reduced by EGFRtk inhi-
bition.24
The induction of neovascularization results from the
balance between pro-angiogenic and anti-angiogenic
factors.25 In this study, we determined the mechanism by
which the chronic inhibition of EGFRtk and ERK1/2 en-
hanced ischemia-induced neovascularization and blood
flow recovery in type 2 diabetic mice. It is well estab-
lished that the NO-cGMP pathway, as an intermediate
signaling pathway, regulates VEGF-dependent neovas-
cularization.26–28 In the present study we demonstrated
that eNOS phosphorylation and expression, and cGMP
levels were significantly reduced in diabetic mice com-
pared with control mice, which suggests that the eNOS
pathway is compromised and participates in impaired
total and phosphorylated EGFR (n  5), (C) total and phosphorylated eNOS
and diabetic mice with or without AG1478 (AG) or U0126 (U0). A–D: Results
n; *P  0.05 for diabetic versus control, †P  0.05 indicating a significant
iabetic versus diabetic treated with AG1478.5), (B)
controlneovascularization. Importantly, the chronic inhibition of
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tivity and ischemia-induced neovascularization, which
suggests that the eNOS pathway is regulated by EGFRtk
and ERK1/2 activity. Further studies are needed to delin-
eate the mechanism linking EGFRtk and ERK1/2 to eNOS
activity and the downstream signaling molecule cGMP. It
is well established that VEGF is critical for neovascular-
ization.29 It is surprising that VEGF level is augmented in
diabetic mice indicating that the binding and signaling
could be compromised. These data are in agreement
with previous studies showing an increase in VEGF levels
with reduced VEGF signaling in type 2 diabetes.30–33 The
chronic inhibition of EGFRtk and ERK1/2 reduced VEGF
levels and was associated with improved ischemia-in-
duced neovascularization indicating an improvement in
VEGF binding and signaling. We suggest that EGFRtk
and ERK1/2 inhibition improves VEGFR binding and sig-
naling, and this could explain the reduction in VEGF
levels associated with increased neovascularization.
There is an association between ERK1/2 and angio-
genesis.34 In this study, we found an increase in ERK1/2
expression and phosphorylation in diabetic mice. The
chronic inhibition of ERK1/2 significantly reduced ERK1/2
phosphorylation, which was associated with enhanced
ischemia-induced neovascularization in diabetic mice.
These data suggest that ERK1/2 is an anti-angiogenic
factor in type 2 diabetic mice. An effect on ischemia-
induced neovascularization was not seen in control mice
treated with ERK1/2, indicating that ERK1/2 is not an
important factor in neovascularization. These data are not
in agreement with a previous study showing that GRb2 is
important in angiogenesis signaling through Akt and
ERK1/2.34 We previously reported that nitric oxide inhibits
ERK1/2 phosphorylation.28 Our current findings are in
agreement with our previous study.35,36 Diabetic mice
have less nitric oxide, which leads to an increase in
ERK1/2 phosphorylation and causes impaired ischemia-
induced neovascularization. ERK1/2 is a downstream
signal for EGFRtk; therefore, it is more likely that inhibiting
EGFRtk would have a readout similar to that of the inhi-
bition of ERK1/2. In addition, a previous study reported
that ERK1/2 activation was suppressed in the presence
of AG1478, while the phosphorylation of JNK and p38
were not affected.37 It was also reported that EGF in-
creases ERK1/2 activation.38 Thus, the chronic treatment
of diabetic mice with ERK1/2 inhibitor significantly en-
hanced eNOS expression and phosphorylation, associ-
ated with augmented ischemia-induced neovasculariza-
tion. However, eNOS mRNA levels were similar all groups
of mice, which indicate a posttranscriptional regulation
event39–42 and possible eNOS mRNA degradation in
type 2 diabetes. Our data indicate a potential interaction
between eNOS pathway, ERK1/2, and ischemia-induced
neovascularization in diabetic mice. Further studies are
needed to elucidate the mechanism of the interaction
between nitric oxide and ERK1/2 in respect to neovascu-
larization in type 2 diabetes.
In conclusion, we observed that in type 2 diabetic
mice, chronic inhibition of EGFRtk and ERK1/2 re-estab-
lished ischemia-induced neovascularization and hind-
limb blood flow recovery. Therefore, EGFRtk and ERK1/2should be potential targets for therapeutic strategy to
protect against impaired ischemia-induced vascular pa-
thology in type 2 diabetes.
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